United Kingdom (UK) Below is a list of our latest research posters, presentations and brochures, available for download and viewing. Please contact us with any questions. If you’re looking for more general background information on antibodies and antibody engineering, be sure to check out the Antibody Resource section of our website.
Posters
Prometheus™: a novel approach for engineering manufacturable humanized antibodies
This poster describes our humanization approach, which was informed by analyzing manufacturability data for more than 100 therapeutic antibodies to identify preferential manufacturing properties. The poster also describes an antibody humanization case study, in which we created 25 different humanized variants with increased titers compared to the original chimeric antibody. The three winning candidates displayed no detectable aggregation, an approximately two-fold increase in activity, and a minimum 16-fold increase in titer compared to the chimeric antibody.
Fully murine knob-into-hole bispecific as surrogate molecule for drug development models
This poster reports the generation of a fully murine, knob-into-hole (KIH), heavy-chain heterodimerizing, bispecific antibody format. It is the first commercially available KIH bispecific antibody platform for creating fully murine surrogate molecules for syngeneic evaluation of target combinations. The poster also provides functional characterization of an anti-mCD3ε:TRP-1 bispecific antibody, capable of selectively recruiting T-cells to TRP-1+ cancer cells for increased cytotoxic effector function, as a proof of concept.
Consistent, long-term PD1 blockade using a syngeneic, engineered anti-PD1 antibody
This poster compares the efficacy of the anti-mouse PD1 clone RMP1-14 in its original rat IgG2a format against a recombinantly engineered mouse IgG2a Fc Silent™ version at different doses over a period of 70 days in a non-immunogenic HEP1-6 liver cancer model. Syngeneic mouse IgG2a Fc Silent™ antibodies showed better dose efficacy and more homogenous treatment responses, reducing tumor size in mouse models more effectively than the traditional rat monoclonal antibody.
An integrated workflow for recombinant antibodies in lateral flow immunoassay development
Developing a successful diagnostic test or assay requires a secure supply chain of high-quality reagents. This poster presents an integrated workflow for introducing recombinant antibodies into lateral flow immunoassay development. Recombinant antibody technology allows you to obtain highly reliable antibodies tailored to your specific assay, enabling superior performance for the entire lifespan of your diagnostic.
Periodic Table of Antibodies
Absolute Antibody has engineered and produced more than 140 different antibody formats for our customers, as illustrated by our Periodic Table of Antibodies. The antibody formats are categorized in the table by number of specificities, starting with single target antibodies and moving into bispecific and trispecific antibodies. The antibodies are further categorized as Fc containing antibodies, antibody fragments and Fc fusion proteins. Learn what each format is by downloading our Periodic Table of Antibodies poster with the full legend.
Presentations
Why go recombinant? Take your experiments further with high reproducibility and antibody engineering
Presenter: Michael Fiebig, PhD, VP Product Portfolio & Innovation, Absolute Antibody
Recombinant antibodies offer significant benefits compared to traditional hybridoma-produced monoclonal antibodies, including ensuring bath-to-batch reproducibility and enabling antibody engineering. Antibody engineering allows researchers to improve experimental design and develop complex controls with absolute precision.
Taking the training wheels off transient expression: rapid antibody production for pandemics
Presenter: Ian Wilkinson, PhD, Absolute Antibody CSO
In a pandemic, three critical things need to be developed quickly: diagnostics, therapeutics and vaccines. Transient expression of antibodies and other proteins offers an important tool for rapid scale-up and production. It is a well-established technique that, if applied correctly, could make future pandemic responses quicker.
Scaling up and scaling out: pushing the boundaries of transient protein production
Presenter: Ian Wilkinson, PhD, Absolute Antibody CSO
While transient yields have improved drastically in the last decade, scalable systems are time-consuming and costly to implement. Absolute Antibody has developed systems which scale up and scale out protein expression and purification, enabling the rapid and cost-effective production of milligram-to-gram quantities of large panels of proteins.
Product and Service Brochures
- Recombinant Antibody Services
- Recombinant Antibody Catalog
- Multi-Hybridoma Conversion Service
- Recombinant Antibodies for Diagnostic Developers
- VivopureX™ Recombinant Antibodies for In Vivo Research
- Recombinant Coronavirus Antibodies
- Murine Bispecific Antibody Reagents